AbbVie (NYSE: ABBV) inches down in pre trading session on Wednesday as the firm announces that it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index for the eleventh year in a row (DJSI North America). Furthermore, on the 2022 S&P Global Corporate Sustainability Assessment, AbbVie received the top score in the biotech category (CSA). Since its inception in 2013, AbbVie has been included on the DJSI World and DJSI North America every year.
The S&P Global CSA is an annual assessment of firms’ sustainability efforts. The CSA results, which include over 10,000 firms globally and focus on industry-specific and financially important sustainability criteria, guide inclusion in the DJSI. AbbVie’s successes in the biotech industry, as well as admission in the DJSI World and DJSI North America, indicate its continued commitment to promote ESG efforts that help to its sustainable growth and have a good influence on future generations.
AbbVie’s VP of corporate responsibility and worldwide philanthropy, Claudia Carravetta stated that as a company established on sustainable practices, they are committed to implementing policies that benefit patients, employees, communities, and the environment. They are thrilled to be included in this year’s Dow Jones Sustainability World Index and to have obtained the highest score in the biotech industry.
On the other hand, AbbVie (NYSE: ABBV) reported fresh results from Cohort 3 of its Phase 2 REFINE trial of experimental navitoclax in conjunction with ruxolitinib in JAK inhibitor-naive myelofibrosis patients (MF). According to the preliminary findings, the combination of navitoclax and ruxolitinib reduced bone marrow fibrosis (BMF) and variant allele frequency (VAF) for frequent genetic variants observed in persons with myelofibrosis, indicating possible disease modification. 1 The findings were presented orally (abstract #237) at the 64th Annual Meeting & Exposition of the American Society of Hematology (ASH).
The VP and global head of oncology clinical development of AbbVie, Mohamed Zaki said, “While the current standard of care for patients with myelofibrosis can improve disease symptoms, impact on underlying disease biology is limited. It is our hope that patients have an option that goes beyond symptom control. “Consistent with previous evidence, these results suggest navitoclax combination may have disease modifying potential, both as an anti-fibrosis agent and by reducing variant allele frequency of driver mutations.”
